Matt Henriksen

Appreciate it.

And I'd like to thank our listeners for tuning in.

We hope you enjoy us for future episodes.

And if you want to stay up to date, please click the subscribe button on Spotify or your favorite streaming platform.

Take care.

Welcome to another exciting episode of the Vanguards of Healthcare series.

My name is Matt Henriksen, the medical technology analyst at Bloomberg Intelligence, which is the in-house equity research platform of Bloomberg LP.

We are pleased to have BioLink with us today, including CEO Rich Yang and co-founder, president, and CTO Jared Tangney.

BioLink is a privately held medical device company that is developing bio-wearables, including Shine, the first glucose sensor with no hypodermic needle for insertion.

Rich and Jared, thank you both for joining us today.

Glad to be here.

Thank you.

Thanks, Matt.

And why don't we just start with both of your career paths?

Jared, I might start with you first, because as a co-founder, you took the steps to see an unmet need in really a market that seems to be innovating very, very quickly.

So just curious your thoughts of how you came about founding this company.

Rich, you joined a little bit later, but your career was very well established in the diabetes space beforehand.

Why don't you let the listeners know your career path that got you to BioLink?

Yeah.

And I mean, we will jump into the technology in a few minutes, but this is an interesting episode for me personally, because we're talking about, usually in these episodes, I talk about an antiquated technology that's being disrupted by new innovation.